Pre-treatment blood samples will be collected: 8 samples

Breast Cancer

Pre-treatment blood samples will be collected for downstream analyses:
Three 6 ml EDTA samples for proteomic and genomic work package
One 6 ml dry sample for auto-antibodies analysis in the immunology work package
Two 4 ml EDTA samples for DNA extraction in the immunology work package
Two 2.5 ml PAX Gene sample for RNA extraction in the immunology work package and the non-irradiated control in the genomic work package

Blood sample

Institut régional du Cancer de Montpellier

Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE)

Radiation-induced Late Side-effects: Predictive Role of New Biomarkers for Selecting Hypersensitive Patients to Ionizing Radiation in Breast Cancer (BIORISE)

Confirm the predictive value, of a blood test based on the dosage of a panel of five (5) proteins: AK2 - IDH2 - ANX1- APEX1 - HSC70 in radiation-induced late side effects after breast-conserving surgery and curative intent adjuvant radiotherapy.

Institut du Cancer de Montpellier - Val d'Aurelle

CB-839 administered as oral capsules two (BID) or three times daily (TID) in 21-day cycles until disease progression or unacceptable toxicity

CB-839 administered as oral capsules twice daily (BID) in combination with standard dose paclitaxel in 28-day cycles until disease progression or unacceptable toxicity

CB-839 administered as oral capsules twice daily (BID) in combination with standard dose everolimus in 28-day cycles until disease progression or unacceptable toxicity

CB-839 administered as oral capsules twice daily (BID) in combination with standard dose erlotnib in 28-day cycles until disease progression or unacceptable toxicity

CB-839 administered as oral capsules twice daily (BID) in combination with standard dose docetaxel in 21-day cycles until disease progression or unacceptable toxicity

CB-839 administered as oral capsules twice daily (BID) in combination with standard dose cabozantinib in 28-day cycles until disease progression or unacceptable toxicity

Solid Tumors

Triple-Negative Breast Cancer

Non Small Cell Lung Cancer

Renal Cell Carcinoma

Mesothelioma

Fumarate Hydratase (FH)-Deficient Tumors

Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST)

Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors

Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations

Tumors Harboring Amplifications in the cMyc Gene

CB-839

CB-839 in combination with standard dose paclitaxel

Pac-CB

CB-839 in combination with standard dose everolimus

CB-839 in combination with standard dose erlotnib

CB-Erl

CB-839 in combination with standard dose docetaxel

CB-839 in combination with standard dose cabozantinib

CB-Cabo

UCSF Helen Diller Family Comprehensive Cancer Center

Stanford University Medical Center

Florida Cancer Specialists

Winship Cancer Institute of Emory School of Medicine

NIH - NCI - Center for Cancer Research

Massachusetts General Hospital

Beth Israel Deaconess Medical Center

Dana-Farber Cancer Institute

Columbia University Medical Center

Memorial Sloan Kettering Cancer Center

University of Pennsylvania, Abramson Cancer Center

Tennessee Oncology, PLLC

University of Texas MD Anderson Cancer Center

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

isocitrate dehydrogenase/рак на гърдата

Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE)

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Най-пълната база данни за лечебни билки, подкрепена от науката